The Bull Case For 10x Genomics (TXG) Could Change Following Mixed Q1 Results And Reaffirmed Guidance

10x Genomics NewsThe Bull Case For 10x Genomics (TXG) Could Change Following Mixed Q1 Results And Reaffirmed Guidance - simplywall.st

CellThe temporal architecture of the seminiferous epithelial cycle revealed by spatial transcriptomics

CellCell-autonomous control of CAR signaling and receptor shedding via ADAM17-mediated proteolysis

CellTransplanting light-dependent reactions for mammalian eye photosynthesis

Endpoints NewsMakary resigns; Biogen reports Alzheimer’s data; and more

10x Genomics NewsPrecision Trading with 10x Genomics Inc. (TXG) Risk Zones - Stock Traders Daily

JEOLJEOL Ltd stock (JP3612800009): earnings momentum and semiconductor demand in focus - AD HOC NEWS

FierceBiotechTransforming neurodegenerative disease treatment

Thermo FisherIs Thermo Fisher (TMO) Quietly Reinforcing Its End‑to‑End Biopharma Role With New IBTROZI Duties? - simplywall.st

FierceBiotechAdvances and Opportunities in Dual Chamber Injectables

FierceBiotechAchieving Effective Manufacturing Scaleup for Clinical and Commercial Success

FierceBiotechUtilizing AI to Facilitate Combination Product Development